News
Clinical Topics
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Breaking Barriers
Face Off
From All Angles
Meeting of the Minds
Morning Rounds
OncView
Podcasts
Readout 360
Sponsored Media
Training Academy
Treatment Algorithms with the Oncology Brothers
Conferences
Publications
All Journals
Editorial Board
For Authors
Year in Review
Events
Frontline Forum
Satellite Sessions
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Career Center
Subscribe
Choose Specialty
Adverse Effects
Biomarkers
Brain Cancer
Breast Cancer
Breast Cancer
Breast Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Head & Neck Cancer
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hormone-related Cancers
Immunotherapy
Infection
Infection
Leukemia
Lung Cancer
Lung Cancer
Lung Cancer
Lymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Choose Specialty
Adverse Effects
Biomarkers
Brain Cancer
Breast Cancer
Breast Cancer
Breast Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Genitourinary Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Gynecologic Cancers
Head & Neck Cancer
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hematologic Oncology
Hormone-related Cancers
Immunotherapy
Infection
Infection
Leukemia
Lung Cancer
Lung Cancer
Lung Cancer
Lymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight
News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe
Advertisement
ASCO 2024 Updates in the Treatment of Renal Cell Carcinoma and Evolving Data on Non-Clear Cell Renal Cell Carcinoma
: Episode 8
ASCO 2024: Abstract 4512 Overview
July 17, 2024
By
Martin H. Voss, MD
Moshe Ornstein, MD, MA
Opinion
Video
Medical experts in renal cell carcinoma provide an overview of abstract 4512 presented at ASCO 2024.
EP: 1.
Overview of RCC Histology and Incidence Rates
EP: 2.
CLEAR Trial Updates From ASCO 2024
EP: 3.
TKIs, Disease Progression and Subsequent Therapy in RCC
EP: 4.
ASCO 2024 Updates: nccRCC + Chromophobe RCC
EP: 5.
PAPMET Phase II Trial Advances Cancer Treatment Landscape
EP: 6.
Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis
EP: 7.
Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence
Now Viewing
EP: 8.
ASCO 2024: Abstract 4512 Overview
EP: 9.
Key Takeaways in Renal Cell Carcinoma from Abstract 4512
EP: 10.
Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials
Recent Videos
Related Content
Related Content
Advertisement